



Markets
/
Stocks
/
nasdaq-abbv
/

AbbVie Inc

ABBV

View Detailed Chart

186.070USD

+5.699+3.16%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

328.46BMarket Cap

77.50P/E TTM



AbbVie Inc

186.070

+5.699+3.16%

Company

Intraday

30m

Today

+3.16%

5 Days

+7.56%

1 Month

-7.57%

6 Months

-0.95%

Year to Date

+4.71%

1 Year

+16.57%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 28 analysts

BUY

Current Rating

214.012

Target Price

15.02%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

AbbVie Inc

ABBV

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(0)

Neutral(0)

Buy(0)

Indicators

Sell(0)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

RSI(14)

STOCH(KDJ)(9,3,3)

ATR(14)

CCI(14)

Williams %R

TRIX(12,20)

StochRSI(14)

Moving Average

Sell(0)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

MA10

MA20

MA50

MA100

MA200

News

Berenberg raises AbbVie PT on higher immunology drug sales

** Berenberg raises PT on drugmaker AbbVie ABBV.N to $195 from $165, citing higher immunology drug sales ** New PT is a 8.7% downside to stock's last close** Brokerage says AbbVie knows the autoimmune market well ** Says co reduced exposure to antirheumatic drug Humira and bolstered cash flows t...

ReutersWed, Mar 12

US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections

Feb 7 (Reuters) - AbbVie ABBV.N said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria.AbbVie and co-developer Pfizer's PFE.N drug, Emblaveo, is approved in combination with an...

ReutersFri, Feb 7

Company

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Company codeABBV

CompanyAbbVie Inc

CEOMr. Robert A. Michael, CPA

Websitehttps://www.abbvie.com/